National Alliance of State and Territorial AIDS Directors

Recent papers from National Alliance of State and Territorial AIDS Directors

1. Ten-Year Cost Projections for Medicare Beneficiaries 65 Years or Older With HIVJAMA Network Open · 2026
2. Long-Acting Injectable Cabotegravir Use and Persistence Over 2 YearsJAMA Network Open · 2026
3. Increasing access to STI testing through addition of at-home syphilis testing to the TakeMeHome self-testing programme in Los Angeles County and North CarolinaSexually Transmitted Infections · 2026
4. State AIDS Drug Assistance Programs’ Contribution to the US Viral Suppression, 2015–2022Clinical Infectious Diseases · 2026
5. Characterizing AIDS Drug Assistance Program Practices and Policies for Sustained Viral Suppression Using the Consolidated Framework for Implementation Research: Protocol for a Qualitative StudyJMIR Research Protocols · 2026
6. Telemedicine Preexposure Prophylaxis Prescribing From a Large Online US CompanyJAMA Network Open · 2025
7. Establish a PrEP (Pre-Exposure Prophylaxis) Epidemiology, Modeling, and Surveillance (PREMISE) System to Analyze Trends in PrEP Uptake and the Impact of PrEP Programs and Policies: Protocol for a Natural Experiment and Modeling Study in the United StatesJMIR Research Protocols · 2025
8. Cross-Jurisdictional Data Sharing: Use of the ATra Black Box for Deduplicating Cases in the National HIV Surveillance SystemPublic Health Reports · 2025
9. Facilitated Telemedicine as a Patient-Centered, Sociotechnical Intervention to Integrate Hepatitis C Treatment Into Opioid Treatment Programs and Overcome the Digital Divide Among Underserved Populations: Qualitative StudyJMIR Public Health and Surveillance · 2025
10. State AIDS Drug Assistance Programs’ Contribution to the United States’ Viral Suppression, 2015-20222025
11. State-level variation in access to long-acting injectable antiretroviral therapy for HIV in the United StatesHealth Affairs Scholar · 2025
12. The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021—December 2022Vaccine · 2024
13. Advancing research, awareness, screening, and linkage to care to eliminate HDV in the U.S.Hepatology Communications · 2023
14. Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018–2020Journal of Pharmaceutical Policy and Practice · 2023
15. Shifting the narrative: equity, evidence, effectiveness, and innovation in the era of Ending the HIV EpidemicInternational Journal for Equity in Health · 2022
16. Economic benefits of the United States’ AIDS drug assistance Program: A systematic review of cost analyses to guide research and policy prioritiesPreventive Medicine Reports · 2022
17. A three-year randomized community trial of community support workers in rural Ethiopia to promote retention in HIV careAIDS Care · 2022
18. The Organization, Content, and Case-Finding Effectiveness of HIV Assisted Partner Services in High HIV Morbidity Areas of the United StatesJAIDS Journal of Acquired Immune Deficiency Syndromes · 2022
19. Timely initiation of HIV antiretroviral therapy in Haiti 20042018: a retrospective cohort studyRevista Panamericana de Salud Pública · 2021
20. Regional Disparities in Qualified Health Plans’ Prior Authorization Requirements for HIV Pre-exposure Prophylaxis in the United StatesJAMA Network Open · 2020